Which Prescription Weight-Loss Medication Is Most Effective?

What is the most effective weight loss medication right now?

For the specific comparison studied, tirzepatide produced the larger average weight loss, according to the 2025 New England Journal of Medicine SURMOUNT-5 trial. In that 72-week trial of 751 adults with obesity and without type 2 diabetes, mean weight change was 20.2% with tirzepatide and 13.7% with semaglutide. That is useful evidence, not a promise about an individual result.

The word “effective” needs more than one column on a chart. Wegovy is a GLP-1 receptor agonist, while Zepbound is a dual GIP and GLP-1 receptor agonist. The FDA's 2025 Wegovy label and 2026 Zepbound label authorize them alongside a reduced-calorie diet and increased physical activity for adults with obesity, or for adults with overweight plus at least one weight-related condition; Wegovy also has an adolescent indication beginning at age 12, while Zepbound also has an adult indication for moderate-to-severe obstructive sleep apnea with obesity.

The practical point is plain: average efficacy is only one part of eligibility. Bring a full medication list, relevant health history, pregnancy plans, and questions about coverage and out-of-pocket cost to the appointment. Public data supplied here do not establish what any insurer will cover.

Is tirzepatide more effective than semaglutide for weight loss?

Yes, tirzepatide was more effective than semaglutide for average weight loss in the 2025 SURMOUNT-5 head-to-head trial, but that result applies to the adults studied rather than every patient. At week 72, 48.4% of tirzepatide participants reached at least 20% weight loss, compared with 27.3% of semaglutide participants, according to the 2025 NEJM report.

The same 2025 trial found mean waist-circumference changes of 18.4 centimeters with tirzepatide and 13.0 centimeters with semaglutide. A bigger average change does not make side effects, contraindications, access, or a person's medical priorities disappear. It simply gives the discussion a better starting point.

Both groups most commonly reported gastrointestinal adverse events, which were usually mild to moderate and occurred primarily during dose escalation in the 2025 NEJM trial. That timing matters. A useful clinician conversation separates a tolerable, expected symptom from a symptom that needs reassessment rather than treating all discomfort as the same thing.

How much weight can people lose on Wegovy or Zepbound?

Trial results show meaningful average loss, but the range for an individual is uncertain and depends on the studied population, continued treatment, and tolerability. In the 2021 STEP 1 body-composition analysis, semaglutide was associated with 15.0% mean body-weight loss over 68 weeks, compared with 3.6% with placebo, alongside lifestyle intervention.

For tirzepatide, the 2025 NEJM head-to-head trial reported 20.2% mean loss over 72 weeks, versus 13.7% for semaglutide. In the 2024 JAMA SURMOUNT-4 trial, participants completed a 36-week tirzepatide lead-in with 20.9% mean weight reduction; people who continued treatment had 25.3% mean loss from the study start through week 88, while those switched to placebo had 9.9% mean loss over that full period.

Those numbers are not a scoreboard for a clinician visit. They are a reminder to ask what outcome would count as meaningful, how side effects will be reviewed, and what happens if the medication is unavailable or discontinued. For readers weighing research participation, Should I Join a Weight-Loss Clinical Trial? explains considerations that are separate from routine clinical care.

Which weight loss medication has the fewest side effects?

No provided trial or FDA label establishes one of these medicines as having the fewest side effects for every person. The FDA's 2026 Zepbound label and 2025 Wegovy label both list nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, and reflux-related symptoms among common adverse reactions, so the more useful question is which risks and symptoms are acceptable in a particular medical context.

The 2026 Zepbound label reports severe gastrointestinal adverse reactions in 1.7% of patients receiving 5 milligrams, 2.5% receiving 10 milligrams, and 3.1% receiving 15 milligrams, compared with 1.0% receiving placebo in pooled weight-reduction trials. The 2025 Wegovy label reports cholelithiasis in 1.6% of Wegovy-treated adults versus 0.7% with placebo, and cholecystitis in 0.6% versus 0.2%, respectively, in adult weight-reduction trials.

Neither label supports casually ignoring symptoms. Ask which symptoms warrant a call, how existing digestive symptoms affect the decision, and how other medications fit into the plan. Both FDA labels list a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 as a contraindication; the labels also list prior serious hypersensitivity to the respective medicine as a contraindication.

How should muscle preservation and long-term planning fit the conversation?

Lean tissue deserves a place in the conversation because scale weight is not the whole result. In the 2021 Journal of the Endocrine Society STEP 1 analysis, semaglutide participants had a 19.3% reduction in total fat mass and a 27.4% reduction in visceral fat mass, but total lean body mass also declined by 9.7%. Lean mass rose by 3.0 percentage points as a share of total body mass.

That is not evidence that one universal protein target or exercise routine prevents muscle loss; the supplied research does not test such a plan. It is evidence for asking a more complete question: how will protein intake, resistance training, physical function, rapid weight change, and any need for monitoring be handled? The process matters more than a single reading on the scale.

Long-term planning matters for the same reason. In the 2024 JAMA withdrawal trial, 89.5% of participants continuing tirzepatide maintained at least 80% of their initial weight loss at week 88, compared with 16.6% after switching to placebo. Discussing stop conditions and regain risk at the beginning is less glamorous than comparing percentages, but it is the part that prevents false certainty.